Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta variable 4-3 encodes the variable (V) region of the beta chain of the T cell receptor, forming part of the antigen-binding domain on alpha-beta T lymphocytes. The TCR beta variable region is created through V(D)J recombination, generating immense diversity for antigen recognition. The receptor is membrane-bound, expressed exclusively on the surface of T cells, and essential for adaptive immune responses by mediating recognition of peptide-MHC complexes presented by antigen-presenting cells. Variations in TRBV4-3 and related variable regions can influence T cell function and are linked to autoimmune disease, cancer progression, immunotherapy responses, and serve as biomarkers for immune-related adverse events.
Drugs such as checkpoint inhibitors indirectly modulate TRBV4-3-expressing T cells by blocking negative regulators of T cell activation, resulting in enhanced immune activity against cancer or pathogens
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor beta variable 4-3 (TRBV4-3).